Òâ´óÀû¹ó±ö»á¹ÙÍø

²úÆ·ÖÐÐÄ

ÁªÏµÒâ´óÀû¹ó±ö»á¹ÙÍø

+86-010-82156767

ÏúÊÛרÓãº

+86-010-62983737 

+86-15522507305 

+86-15522507319 

+86-15522507326

µØµã£º±±¾©Êк£µíÇøÎ÷С¿Ú·66ºÅÖйش嶫Éý¿Æ¼¼Ô°C-1Â¥Èý²ã

undefined
+
  • undefined

Fmoc Amine PEG Acetic Acid

²úÆ·´úºÅ£º

FMOC-PEG-CM

²úÆ·´¿¶È£º

¡Ý 95%

°ü×°¹æ¸ñ£º

1g, 10g, 100gµÈ£¨ÌØÊâ°ü×°ÐèÊÕÈ¡·Ö×°Óöȣ©

·Ö×ÓÁ¿£º

2000 Da,3500 Da, 5000 Da, 7500 DaµÈ

²úÆ·×Éѯ£º

¿ÆÑпͻ§Ð¡ÅúÁ¿Ò»¼ü²É¹ºµØµã£¨Ð¡ÓÚ5¿Ë£©

Á¢¼´Ïµ¥
  • ²úÆ·ÃèÊö
  • ²Î¿¼ÎÄÏ×

  • ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Éú²úµÄÒìË«¹¦Ð§Ü̼×ÑõôÊ°±»ù¾ÛÒÒ¶þ´¼ôÈËá²úÆ·Öк¬ÓÐÊܱ£»¤µÄ°·»ùÍÅ £¬Í¨³£ÓÃ×÷Á½ÖÖ²î±ð»¯Ñ§ÎïÖʵĽ»Áª¼Á»ò¼ä¸ôÎï¡£´ËÒ칦ЧPEGÑÜÉúÎïÖеÄPEG²¿·Ö¿ÉÌṩˮÈÜÐÔ¡¢ÉúÎïÏàÈÝÐÔ¼°ÈáÐÔ¡£´Ë²úƷרÃÅÓ¦ÓÃÓÚ¿¹ÌåżÁªÒ©Îï(ADC¡¯s)µÄ¿ª·¢¡£

    ²úÆ·±àÂë

    ²úÆ·´úºÅ

    A5081

    FMOC-PEG2000-CM

    A5082

    MAL-PEG2000-CM

    A5083

    MAL-PEG5000-CM

    A5084

    MAL-PEG7500-CM

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼ÌṩFMOC-PEG-CM·Ö×ÓÁ¿2000 Da,3500 Da, 5000 Da, 7500 DaµÄ²úÆ·1¿ËºÍ10¿Ë°ü×°¡£

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Ìṩ·ÖװЧÀÍ £¬ÐèÒªÊÕÈ¡·Ö×°ÓÃ¶È £¬Èç¹ûÄúÐèÒª·ÖװΪÆäËû¹æ¸ñÇëÓëÎÒÃÇÁªÏµ¡£

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Í¬Ê±ÌṩÆäËû·Ö×ÓÁ¿µÄFMOC-PEG-CMÑÜÉúÎï²úÆ· £¬ÈçÄãÐèÒªÇëÓëÎÒ˾sales@jenkem.comÁªÏµ¡£

    ¡¡¡¡Òâ´óÀû¹ó±ö»á¹ÙÍø¿Æ¼¼Ìṩ´óÅúÁ¿Éú²ú²úÆ·¼°GMP¼¶±ð²úÆ· £¬ÈçÐ豨¼ÛÇëÓëÎÒÃÇÁªÏµ¡£

     

  • ¡¡¡¡References:

    ¡¡¡¡1. Veiman, K.-L., et al., PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo, Journal of Controlled Release, 2015, 209: 238-247.

    ¡¡¡¡2. Guarnieri, D., et al., Tumor©\activated prodrug (TAP)©\conjugated nanoparticles with cleavable domains for safe doxorubicin delivery, Biotechnology and Bioengineering, 2015, 112(3): 601-611.

    ¡¡¡¡3. Kuo, C.-H., Inhibition of atherosclerosis-promoting microRNAs via targeted polyelectrolyte complex micelles J. Mater. Chem. B, 2014, 2, 8142-8153.

²úƷѯ¼Û

ÍøÕ¾µØͼ